news

한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina

On the 5th, the official website of Songshan Lake High-tech Zone released the "List of Proposed Funding for Dongguan Songshan Lake Biomedicine Industry Special Funds in 2023", which plans to provide funding to 30 companies (units) including Guangdong East Sunshine Pharmaceutical Co., Ltd., with a proposed reward and subsidy amount of more than 72.3 million yuan.

Public information shows that this funding is based on the "Notice on Issuing the Implementation Rules (Trial) on Several Measures to Promote the High-Quality Development of Dongguan Songshan Lake Biomedicine Industry" (Songshan Lake Development [2023] No. 17) and the "Notice on Organizing the Application for Dongguan Songshan Lake Biomedicine Industry Funds". The 2023 Dongguan Songshan Lake Biomedicine Industry Fund Application was carried out. After preliminary review of the projects applied for by relevant units, it is planned to provide funding to 30 companies (units) that have passed the review, including Guangdong East Sunshine Pharmaceutical Co., Ltd.

The projects to be rewarded and subsidized this time include new drug development and registration rewards, subsidies for generic drug consistency evaluation, medical device R&D funding, market access qualification rewards, scale-up rewards, market promotion subsidies, and industrial premises rental subsidies.

A reporter from Nandu sorted out the list of proposed funding and found that Guangdong East Sunshine Pharmaceutical Co., Ltd. is expected to receive the highest amount of subsidies, a total of 21.4 million yuan, of which 14.9 million yuan is expected to be awarded for new drug development and registration awards, and 6.5 million yuan is expected to be awarded for generic drug consistency evaluation subsidies.

According to the official website of Guangdong East Sunshine Pharmaceutical Co., Ltd., it was established on December 29, 2003 and is committed to the global development and commercialization of small molecule innovative drugs, biological innovative drugs and similar drugs, first-copy drugs and innovative preparations, covering infectious diseases such as hepatitis B and hepatitis C, tumor diseases such as esophageal cancer, non-small cell lung cancer and acute myeloid leukemia, endocrine and metabolic diseases such as diabetes and other fields.

In addition, Guangdong Bomai Medical Technology Co., Ltd. plans to receive RMB 11 million in subsidies, including RMB 9 million in medical device R&D funding. According to the official website of Guangdong Bomai Medical Technology Co., Ltd., as the Guangdong Province Vascular Intervention Treatment and Medical Device Engineering Technology Center, Bomai Medical has the world's leading balloon and interventional catheter technology and a number of global exclusive products, and its products are sold in more than 70 countries and regions including China, the United States, Japan, Europe, the Middle East, and Latin America.

Public data shows that Songshan Lake has gathered more than 500 biopharmaceutical companies, including East Sunshine, Hansen Pharmaceuticals, Bogong Technology, Bomei Medical, Jinmeiji and other biopharmaceutical companies, forming a solid foundation for industrial development. In recent years, the output value of biopharmaceuticals in Songshan Lake has grown rapidly at an annual rate of 30%, demonstrating a strong development momentum.

Written by: Southern Metropolis Daily reporter Liang Jindi